The goal was to assess the impact of 6 month treatment with liraglutide and maximum tolerated dose of metformin in 30 obese type 2 diabetic patients on cardiometabolic comprehensive management: weight loss, body mass index (BMI) and waist circumference, glycaemic control (fasting glucose, postprandial blood glucose and glycated haemoglobin (HbA1c), systolic and diastolic blood pressure, lipid profile (TC, LDL-C, triglycerides, HDL-C) and atherogenic index of plasma (AIP) as a significant predictor of cardiovascular risk. After 6 months of treatment with liraglutide and maximum tolerated dose of metformin in the study group we observed a statistically significant difference in weight loss (-3,9 kg), BMI (-1.6 kg/m2) and waist circumference (-3,2 cm). There was a statistically significant decrease in fasting plasma glucose (-2,7 mmol/l), postprandial glucose (-3,2 mmol/l) and glycosylated haemoglobin (-1,1 %). We have not observed a statistically significant difference in systolic and diastolic blood pressure, as well as in total and LDL-cholesterol. However, during treatment, there was a shift to less atherogenic lipoprotein phenotype (TAG decrease and HDL-C increase, decreased AIP), with statistically significant differences from baseline. Treatment with liraglutide in combination with metformin resulted in a significant improvement in cardiometabolic risk profile type 2 diabetic patients; it was well tolerated without increasing the risk of hypoglycaemia.